Cell Bio Human TechLtd Valuation

Is A318160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A318160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A318160 (₩3450) is trading below our estimate of fair value (₩86488.73)

Significantly Below Fair Value: A318160 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A318160?

Key metric: As A318160 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A318160. This is calculated by dividing A318160's market cap by their current earnings.
What is A318160's PE Ratio?
PE Ratio	34.2x
Earnings	₩890.31m
Market Cap	₩30.34b

A318160 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.7x
Enterprise Value/EBITDA	4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A318160's PE Ratio compare to its peers?

The above table shows the PE ratio for A318160 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	12.3x
A086060 GeneBioTech Ltd	11.7x	n/a	₩29.6b
A049960 Cell Biotech	7.4x	n/a	₩95.1b
A109960 AP Healthcare	6.9x	n/a	₩103.4b
A251120 BIO-FD&CLtd	23.2x	n/a	₩118.1b
A318160 Cell Bio Human TechLtd	34.2x	n/a	₩30.3b

Price-To-Earnings vs Peers: A318160 is expensive based on its Price-To-Earnings Ratio (34.2x) compared to the peer average (12.3x).

Price to Earnings Ratio vs Industry

How does A318160's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A318160 is expensive based on its Price-To-Earnings Ratio (34.2x) compared to the Asian Biotechs industry average (31.2x).

Price to Earnings Ratio vs Fair Ratio

What is A318160's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A318160 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	34.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A318160's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩521.4b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩20,550.00

1.5%

-31.5%

Medy-Tox

₩869.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,900.00

0.5%

-41.1%

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%